Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $1.89 per share which missed the analyst consensus estimate of $1.98 by 4.55 percent. This is a 25.59 percent decrease over earnings of $2.54 per share from the same period last year. The company reported quarterly sales of $592.100 million which beat the analyst consensus estimate of $588.875 million by 0.55 percent. This is a 1.14 percent increase over sales of $585.400 million the same period last year.